Kleinostheim (ots Ad hoc-Service) -

Ad hoc-announcement edited and sent by DGAP. The sender is solely
responsible for the contents of this announcement.

curasan AG, Kleinostheim,(WKN 549453) is continuing its high-level
growth. The turnover for the specialist in regenerative biomedicne
increased by nearly 48% to DM 15.9 million (compared with 10.8
million last year) in the first nine months of 2000. Last year's
turnover was exceeded this year in just the third quarter. The export
share was 13%, nearly double that of the previous year. After
evaluating the provisional figures, the Executive Board announced
that the EBIT, including proportional depreciations in company value,
should have improved in the same period.

Biologicals and Biomaterials showed a growth trend by achieving
about 40% of the total turnover (compared with 31% the previous
year). One of the most significant growth vehicles is the synthetic
bone regeneration material Cerasorb, which has been vigorously
marketed internationally. The marketing of Cerasorb as a block
material and in fittings, has begun along with the present
granulates, and this should also promote turnover. An international
patent application has been made for the solid forms. The
Pharmaceuticals sector - in particular local anaesthetics,
antibiotics, anaesthetics and a fibrinolytic drug - decreased to
around 60% of earnings (compared with 69% last year) because of the
strong growth of the other two areas.

The Executive Board believes that the company will continue to
grow and that a high-level turnover growth will be achieved at the
end of the business year.

The complete quarterly report will be published on 20 November.

curasan AG Executive Board

Original-Content von: Curasan AG, übermittelt durch news aktuell